P/B
2,7
Cognition Therapeutics
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
$89.1M
Market Cap • 10/7/2026
2007
(19 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,3
EPS
—
Market Cap
Market Cap
89,1M
EV
54,8M
EV/Revenue
0
EV/EBITDA
-1,5
EV/EBIT
-1,5
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-46,6%
Total Yield
-46,6%
Payout
0%
Retained Earnings
-207,1M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
1,5%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
12,7%
CAGR Net Income 5Y
27,8%
CAGR EPS 5Y
-60,3%
CAGR OCF 5Y
41,4%
Leverage
N.D./EBITDA
0,9
Debt/Equity
0%
Current Ratio
7
Quick Ratio
6,9
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!